EWP
GMAB icon

Elevation Wealth Partners’s Genmab GMAB Stock Holding History

Elevation Wealth Partners’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$7.96K Hold
223
– – ﹤0.01% 974
2026
Q2 		$6.13K Buy
+223
New +$5.93K ﹤0.01% 959

Other funds holding GMAB

LWAM
Legacy Wealth Asset Management Woodbury, Minnesota $456M AUM 31.62% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MAM
Marotta Asset Management Charlottesville, Virginia $589M AUM 14.57% 1-Year Est. Return
JWS
Juncture Wealth Strategies Scottsdale, Arizona $390M AUM 19.15% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GWM
Gilpin Wealth Management Denver, Colorado $148M AUM 25.13% 1-Year Est. Return
MGI
Miller Global Investments Dallas, Texas $124M AUM 25.7% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
RWS
Retirement Wealth Solutions Marshfield, Wisconsin $189M AUM 13.41% 1-Year Est. Return

Elevation Wealth Partners's GMAB Position: Q3 2026 in Review

Elevation Wealth Partners held its Genmab (GMAB) position steady in Q3 2026 at 223 shares worth $7.96K. The position accounts for ﹤0.01% of the portfolio, ranked #974.

Elevation Wealth Partners first reported a position in GMAB in Q2 2026 and has held it in 2 quarters since. 13 funds tracked by Wall St. Rank hold GMAB as of Q3 2026.

  • Elevation Wealth Partners held 223 shares of Genmab worth $7.96K as of Q3 2026.
  • Elevation Wealth Partners left its Genmab share count unchanged in Q3 2026.
  • Genmab made up ﹤0.01% of Elevation Wealth Partners's portfolio in Q3 2026, its #974 holding.
  • Elevation Wealth Partners first reported a position in Genmab in Q2 2026 and has held it in 2 quarters since.
  • 13 funds tracked by Wall St. Rank held Genmab as of Q3 2026.

Based on Elevation Wealth Partners's 13F filing for Q3 2026, filed 7 Oct 2026.